A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use

New York, New York, UNITED STATES

New York, NY, April 19, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer that highlights significant, often unrecognized blood loss in cardiac surgery. The paper entitled “Measurement of Blood Loss in Cardiac Surgery: Still Too Much” appears in the April issue of The Annals of Thoracic Surgery.

Study author Mark Nelson, MD of Virginia Commonwealth University stated that the surprising results of his study showed the inadequacy of current methods of evaluating blood loss, including the widespread use of hematocrit and hemoglobin: “Contrary to the long-held belief that red blood cells are largely conserved during cardiac surgery they are in fact reduced by 38%.“ He added, “This data beckons the question of transfusion, should peripheral hematocrit continue to be utilized as a determinant.”

Michael Feldschuh CEO of Daxor stated, “This study highlights the BVA-100’s unique ability to illuminate intravascular fluid derangements that are missed by standard diagnostic tests. With over 500,000 coronary bypass surgeries, 3,200 transplants, and hundreds of thousands of other cardiac and non-cardiac surgeries performed annually in the United State, the need for optimal care and accurate measurement of surgical blood loss is acute.  We see this as a very large and significant additional market for our product and look forward to subsequent research studies planned in this area.”

Surgical and non-surgical anemia caused by blood loss is a common ailment that poses significant risk to patients. Standard tests for determining blood loss or anemia lack the specificity and sensitivity of the BVA-100 test, which precisely quantifies whole blood and red blood cell volume with 98% accuracy.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.